Since the effectiveness of immune checkpoint inhibitors (ICIs) and BRAF and MEK inhibitors have improved advanced melanoma recovery, researchers conducted the study for comparing the cost-utility of these novel agents and their combinations with or without BRAF gene testing guidance for treating newly diagnosed advanced melanoma with unknown BRAF status.
Publications
FDA Grants Fast Track Designation to CMP-001 Combination in Advanced Melanoma
The FDA has granted Fast Track designation to CMP-001 in combination with nivolumab (Opdivo) plus ipilimumab (Yervoy), which will undergo clinical trial development both as a potential extender of time to disease relapse as an initial treatment of patients with unresectable stage III or stage IV melanoma, as well as to improve the overall tumor response rate as treatment of patients with unresectable or metastatic melanoma refractory to prior anti-PD-1 blockade.1
Comorbidity burden on receipt of adjuvant immunotherapy and survival in patients with stage III melanoma: an analysis of the National Cancer Database
Researchers used the National Cancer Database to explore the connection between comorbidity burden, receipt of adjuvant immunotherapy, and survival in patients with stage III melanoma.
Immunotherapy in sinonasal melanoma: treatment patterns and outcomes compared to cutaneous melanoma
In this cohort study, researchers sought to assess whether immunotherapy was correlated with improved survival in sinonasal melanoma (SNM) and to compare the impact of immunotherapy in metastatic sinonasal and cutaneous melanoma.